Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Enrique Alvarez III

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-NEUR General Operations
Phone303/724-8249
    Other Positions
    TitleAssoc Chair
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-NEUR General Operations


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ardakani RV, Crane PD, Pastula DM, Chauhan L, Matthews E, Money KM, Shah A, Piquet AL, Gross RH, Carlson AM, Tyler KL, Corboy JR, Alvarez E, Wolf AB. West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies. Neurol Clin Pract. 2025 Aug; 15(4):e200489. PMID: 40584641.
      View in: PubMed
    2. Col NF, Solomon AJ, Alvarez E, Pbert L, Ionete C, Morales IB, Chester J, Kutz C, Iwuchukwu C, Livingston T, Springmann V, Col H, Ngo L. Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary. Neurodegener Dis Manag. 2025 Apr-Jun; 15(2-3):97-106. PMID: 40329687.
      View in: PubMed
    3. Gross PS, Dur?n-Laforet V, Ho LT, Melchor GS, Zia S, Manavi Z, Barclay WE, Lee SH, Shults N, Selva S, Alvarez E, Plemel JR, Fu MM, Schafer DP, Huang JK. Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. Nat Commun. 2025 Mar 07; 16(1):2283. PMID: 40055369.
      View in: PubMed
    4. Quinn CM, Rajarajan P, Gill AJ, Kopinsky H, Wolf AB, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, Kister I. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications. Neurology. 2024 Dec 10; 103(11):e210003. PMID: 39541548.
      View in: PubMed
    5. Alvarez E, Steinman L, Fox EJ, Hartung HP, Qian P, Wray S, Robertson D, Selmaj K, Wynn D, Mok K, Xu Y, Bodhinathan K, Miskin HP, Cree BAC. Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis. Front Neurol. 2024; 15:1473284. PMID: 39512280.
      View in: PubMed
    6. Gross PS, Laforet VD, Manavi Z, Zia S, Lee SH, Shults N, Selva S, Alvarez E, Plemel JR, Schafer DP, Huang JK. Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. bioRxiv. 2024 May 26. PMID: 38826296.
      View in: PubMed
    7. Ma?ago MM, Cohen ET, Alvarez E, Hager ER, Owens JG, Bade M. Feasibility of Low-Load Resistance Training Using Blood Flow Restriction for People With Advanced Multiple Sclerosis: A Prospective Cohort Study. Phys Ther. 2024 Jan 01; 104(1). PMID: 37815934.
      View in: PubMed
    8. Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 01 01; 81(1):87. PMID: 37983039.
      View in: PubMed
    9. Col NF, Solomon AJ, Alvarez E, Pbert L, Ionete C, BerriosMorales I, Chester J, Kutz C, Iwuchukwu C, Livingston T, Springmann V, Col HV, Ngo LH. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool. Mult Scler Relat Disord. 2023 Dec; 80:105092. PMID: 37931489.
      View in: PubMed
    10. Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G, Ledreux A, Zizzo Z, Lundt M, Alvarez E, Yu X. Plasma IgG aggregates as biomarkers for multiple sclerosis. Clin Immunol. 2023 11; 256:109801. PMID: 37816415.
      View in: PubMed
    11. Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Nov; 79:105009. PMID: 37783194.
      View in: PubMed
    12. Abdelrahman A, Alvarez E. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies. Neurol Clin. 2024 Feb; 42(1):115-135. PMID: 37980110.
      View in: PubMed
    13. Borko TL, Baxter R, Cabrera-Martinez B, Thiruppathi E, Sabalza M, Venkataraman I, Selva S, Rester C, Sillau S, Pastula DM, Bennett JL, Alvarez E, Gross R, Shah A, Kammeyer R, Corboy JR, Kedl RM, Hsieh EWY, Piquet AL. SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients. J Neuroimmunol. 2023 10 15; 383:578192. PMID: 37666038.
      View in: PubMed
    14. Giovannoni G, Alvarez E, Tutton E, Hoffmann O, Xu Y, Vermersch P, Oreja-Guevara C, Trojano M, Gold R, Robles-Cede?o R, Khwaja M, Stadler B, Vandercappellen J, Ziemssen T. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis. Digit Health. 2023 Jan-Dec; 9:20552076231173531. PMID: 37205165.
      View in: PubMed
    15. Zhou W, Graner M, Paucek P, Beseler C, Boisen M, Bubak A, Asturias F, George W, Graner A, Ormond D, Vollmer T, Alvarez E, Yu X. Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis. Cell Death Dis. 2023 04 08; 14(4):254. PMID: 37031195.
      View in: PubMed
    16. Courter RJ, Alvarez E, Enoka RM, Ahmed AA. Metabolic costs of walking and arm reaching in persons with mild multiple sclerosis. J Neurophysiol. 2023 04 01; 129(4):819-832. PMID: 36883754.
      View in: PubMed
    17. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz?lez J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588. PMID: 36811392.
      View in: PubMed
    18. Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec; 26(1):494-502. PMID: 36970763.
      View in: PubMed
    19. Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 08 25; 387(8):704-714. PMID: 36001711.
      View in: PubMed
    20. Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec; 68:104143. PMID: 36031693.
      View in: PubMed
    21. Greenberg BM, Bowen JD, Alvarez E, Rodriguez M, Caggiano AO, Warrington AE, Zhao P, Eisen A. A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Mult Scler J Exp Transl Clin. 2022 Apr-Jun; 8(2):20552173221091475. PMID: 35496758.
      View in: PubMed
    22. Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, H?ring DA, Hauser SL, Kappos L, Kuhle J. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front Immunol. 2022; 13:852563. PMID: 35432382.
      View in: PubMed
    23. Kammeyer R, Mizenko C, Sillau S, Richie A, Owens G, Nair KV, Alvarez E, Vollmer TL, Bennett JL, Piquet AL. Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. Front Neurol. 2022; 13:689975. PMID: 35309573.
      View in: PubMed
    24. Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021; 12:799138. PMID: 35145470.
      View in: PubMed
    25. Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069359. PMID: 35024160.
      View in: PubMed
    26. Alenazy M, Daneshgar Asl S, Petrigna L, Feka K, Alvarez E, Almuklass AM, Enoka RM. Treatment with electrical stimulation of sensory nerves improves motor function and disability status in persons with multiple sclerosis: A pilot study. J Electromyogr Kinesiol. 2021 Dec; 61:102607. PMID: 34710779.
      View in: PubMed
    27. Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cede?o RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. J Med Internet Res. 2021 10 06; 23(10):e29558. PMID: 34612826.
      View in: PubMed
    28. Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, H?ring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 05; 28(6):910-924. PMID: 34605319.
      View in: PubMed
    29. Enoka RM, Almuklass AM, Alenazy M, Alvarez E, Duchateau J. Distinguishing between Fatigue and Fatigability in Multiple Sclerosis. Neurorehabil Neural Repair. 2021 11; 35(11):960-973. PMID: 34583577.
      View in: PubMed
    30. Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurol Clin Pract. 2021 Aug; 11(4):358-361. PMID: 34484934.
      View in: PubMed
    31. Vollmer TL, Nair KV, Williams IM, Alvarez E. Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve. Neurol Clin Pract. 2021 Aug; 11(4):342-351. PMID: 34476126.
      View in: PubMed
    32. Lovett-Racke AE, Yang Y, Liu Y, Gormley M, Kraus E, Graham C, Wray S, Racke MK, Alvarez E, Bass A, Fox E. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. J Neuroimmunol. 2021 10 15; 359:577676. PMID: 34364105.
      View in: PubMed
    33. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170. PMID: 34364034.
      View in: PubMed
    34. Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Liz?e G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5). PMID: 34021033.
      View in: PubMed
    35. Kline PW, Christiansen CL, Hager ER, Alvarez E, Ma?ago MM. Movement compensations during a step ascent task are associated with stair climbing performance in people with multiple sclerosis. Gait Posture. 2021 06; 87:27-32. PMID: 33878510.
      View in: PubMed
    36. Nicholas JA, Shin RK, Alvarez E, Hendin B, Nair KV, Lublin FD. Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. Mult Scler Relat Disord. 2021 04; 49:102715. PMID: 33486401.
      View in: PubMed
    37. Chan A, Rose J, Alvarez E, Bar-Or A, Butzkueven H, Fox RJ, Gold R, Gudesblatt M, Haartsen J, Spelman T, Wright K, Ferraro D, Sola P, Hodgkinson S, Kalincik T, Lechner-Scott J, McGuigan C, Spach K, Chen C, Fam S, Wu F, Miller C. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020 Dec; 10(6):510-519. PMID: 33510947.
      View in: PubMed
    38. Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020; 11:1045. PMID: 33071934.
      View in: PubMed
    39. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454. PMID: 33045496.
      View in: PubMed
    40. Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476. PMID: 32767538.
      View in: PubMed
    41. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487. PMID: 32767531.
      View in: PubMed
    42. Ma?ago MM, Kline PW, Alvarez E, Christiansen CL. Trunk and pelvis movement compensation in people with multiple sclerosis: Relationships to muscle function and gait performance outcomes. Gait Posture. 2020 05; 78:48-53. PMID: 32200163.
      View in: PubMed
    43. Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL?) short forms. Mult Scler J Exp Transl Clin. 2019 Oct-Dec; 5(4):2055217319885986. PMID: 31819803.
      View in: PubMed
    44. Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2020 Feb; 38:101508. PMID: 31715503.
      View in: PubMed
    45. Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L. A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. MDM Policy Pract. 2019 Jul-Dec; 4(2):2381468319879134. PMID: 31667351.
      View in: PubMed
    46. Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. PMID: 31644992.
      View in: PubMed
    47. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402. PMID: 31542710.
      View in: PubMed
    48. Khan M, Ney DE, Kleinschmidt-DeMasters BK, Horton L, Alvarez E, Piquet AL. CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab. Neurol Clin Pract. 2019 Jun; 9(3):273-276. PMID: 31341717.
      View in: PubMed
    49. Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 07 15; 332:187-197. PMID: 31077854.
      View in: PubMed
    50. Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14; 7(1). PMID: 30875812.
      View in: PubMed
    51. Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD. Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes. Mult Scler J Exp Transl Clin. 2019 Jan-Mar; 5(1):2055217319827618. PMID: 30800417.
      View in: PubMed
    52. Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. Neurol Ther. 2019 Jun; 8(1):109-119. PMID: 30706431.
      View in: PubMed
    53. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732. PMID: 30635477.
      View in: PubMed
    54. Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262. PMID: 30847358.
      View in: PubMed
    55. Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan; 27:383-390. PMID: 30502644.
      View in: PubMed
    56. Alvarez E, Mowry EM. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes. Mult Scler. 2019 02; 25(2):187-188. PMID: 30346221.
      View in: PubMed
    57. Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2019 Jan; 27:65-73. PMID: 30342416.
      View in: PubMed
    58. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 08 30; 379(9):846-855. PMID: 30157388.
      View in: PubMed
    59. Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. PMID: 30140580.
      View in: PubMed
    60. Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging. 2018 07; 28(4):399-405. PMID: 29749661.
      View in: PubMed
    61. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93. PMID: 29801915.
      View in: PubMed
    62. Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabil Neural Repair. 2018 01; 32(1):84-93. PMID: 29366377.
      View in: PubMed
    63. Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28; 89(22):2238-2244. PMID: 29093070.
      View in: PubMed
    64. Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep; 3(3):2055217317725102. PMID: 28839949.
      View in: PubMed
    65. Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2018 01; 38(1):44-55. PMID: 28806143.
      View in: PubMed
    66. Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, Pérez de Diego R, Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentín J, Varela-Serrano A, Avendaño-Ortiz J, Alvarez E, Aguirre LA, Pérez-Martínez A, De Miguel MP, Belda-Iniesta C, García-Río F, López-Collazo E. Monocytes inhibit NK activity via TGF-ß in patients with obstructive sleep apnoea. Eur Respir J. 2017 06; 49(6). PMID: 28619958.
      View in: PubMed
    67. Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May; 4(3):e339. PMID: 28382320.
      View in: PubMed
    68. Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL. CD40-Mediated NF-?B Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. J Immunol. 2016 12 01; 197(11):4257-4265. PMID: 27798157.
      View in: PubMed
    69. Jones D, Alvarez E, Selva S, Gilden D, Nagel MA. Proinflammatory cytokines and matrix metalloproteinases in CSF of patients with VZV vasculopathy. Neurol Neuroimmunol Neuroinflamm. 2016 Aug; 3(4):e246. PMID: 27340684.
      View in: PubMed
    70. Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 1:2055217315623800. PMID: 28607711.
      View in: PubMed
    71. Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH. Detection of cortical lesions in multiple sclerosis: A new imaging approach. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 1:2055217315606465. PMID: 28607704.
      View in: PubMed
    72. Hampton CW, Galperin D, Alvarez E, West MS. Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e82. PMID: 25798447.
      View in: PubMed
    73. Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015 Feb 24; 84(8):861. PMID: 25713115.
      View in: PubMed
    74. Alvarez E. Should we start evaluating intrathecal IgM production clinically? Eur J Neurol. 2015 Aug; 22(8):1143-4. PMID: 25557488.
      View in: PubMed
    75. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013 Dec; 19(14):1938-42. PMID: 24277735.
      View in: PubMed
    76. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug; 19(9):1204-8. PMID: 23322500.
      View in: PubMed
    77. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov; 69(11):1482-7. PMID: 22926050.
      View in: PubMed
    78. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011 Sep; 68(9):1156-64. PMID: 21555606.
      View in: PubMed
    79. Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol Clin. 2011 May; 29(2):257-78. PMID: 21439440.
      View in: PubMed
    80. Alvarez E, Zhou W, Witta SE, Freed CR. Characterization of the Bex gene family in humans, mice, and rats. Gene. 2005 Aug 29; 357(1):18-28. PMID: 15958283.
      View in: PubMed
    81. Buytaert-Hoefen KA, Alvarez E, Freed CR. Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. Stem Cells. 2004; 22(5):669-74. PMID: 15342931.
      View in: PubMed
    82. Alvarez E, Westmore M, Galvin RJ, Clapp CL, Considine EL, Smith SJ, Keyes K, Iversen PW, Delafuente DM, Sulaimon S, Zambrano C, Ma L, Sato M, Martin TJ, Teicher BA, Galbreath EJ. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res. 2003 Nov 15; 9(15):5705-13. PMID: 14654555.
      View in: PubMed
    83. Clayton DA, Mesches MH, Alvarez E, Bickford PC, Browning MD. A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat. J Neurosci. 2002 May 01; 22(9):3628-37. PMID: 11978838.
      View in: PubMed
    84. Alvarez EO, Banzan AM. Ventral hippocampal glutamate receptors in the rat: possible involvement in learning mechanisms of an active avoidance response. J Neural Transm (Vienna). 1999; 106(9-10):987-1001. PMID: 10599879.
      View in: PubMed
    85. Alvarez EO, Guerra FA. Effects of histamine microinjections into the hippocampus on open-field behavior in rats. Physiol Behav. 1982 Jun; 28(6):1035-40. PMID: 7111446.
      View in: PubMed
    Alvarez's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (291) concept(s)
    _
    Co-Authors Expand Description
    See all (34) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)